Targeted antigen presentation using crosslinked antibody heteroaggregates - PubMed (original) (raw)
. 1987 Sep 1;139(5):1609-16.
- PMID: 2957430
Targeted antigen presentation using crosslinked antibody heteroaggregates
D P Snider et al. J Immunol. 1987.
Abstract
We have targeted protein antigens to antigen-presenting cells in vitro by using antibody heteroaggregates containing an antibody against a protein antigen covalently crosslinked to an antibody against a target structure on the surface of the antigen-presenting cells. Antigen presentation was assessed by measurement of lymphokine released by antigen-specific T cell hybridomas. Depending on the experimental conditions, the crosslinked antibodies decreased the amount of antigen required to give a response by the hybridomas by factors of 10(2) to 10(3). Enhanced presentation occurred when antigen was targeted to MHC class I and class II molecules, surface immunoglobulin, or Fc gamma receptors on the surface of the murine B cell lymphoma-hybridoma, TA3. An enhancement of antigen presentation also occurred when antigen was targeted to surface IgD, or class I and class II MHC molecules on murine splenic B cells, and when antigen was targeted to class I and class II molecules on irradiated adherent spleen cells. No response was seen when antigen was targeted to Fc gamma R on B cells or adherent spleen cells. The ability of each crosslinked antibody to enhance presentation paralleled the total amount of each that bound to the surface of the antigen-presenting cells. Antigen presentation, mediated by crosslinked antibody, was antigen-specific and I-A restricted. The presentation of one antigen by using crosslinked antibody did not result in enhanced presentation of a second, bystander antigen. These results suggest that a novel means of stimulating immune responses may be possible in vivo, by targeting antigen to surface structures on antigen-presenting cells.
Similar articles
- Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M, Pfeifer J, Stockinger B, Wick MJ. Svensson M, et al. Behring Inst Mitt. 1997 Feb;(98):197-211. Behring Inst Mitt. 1997. PMID: 9382741 Review. - Targeting antigens to antigen presenting cells.
Fossum S, Berg SF, Mjaaland S. Fossum S, et al. Semin Immunol. 1992 Aug;4(4):275-83. Semin Immunol. 1992. PMID: 1391800 Review.
Cited by
- Recombinant antigen delivery to dendritic cells as a way to improve vaccine design.
de Souza-Silva GA, Sulczewski FB, Boscardin SB. de Souza-Silva GA, et al. Exp Biol Med (Maywood). 2023 Oct;248(19):1616-1623. doi: 10.1177/15353702231191185. Epub 2023 Sep 25. Exp Biol Med (Maywood). 2023. PMID: 37750021 Free PMC article. Review. - Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM.
Westhrin M, Blazevski J, Textor A, Abdollahi P, Gopalakrishnan RP, Ngo LT, Hofgaard PO, Heinzelbecker J, Bobic S, Fossum E, Spång HCL, Braathen R, Bogen B. Westhrin M, et al. J Immunother Cancer. 2023 Aug;11(8):e006944. doi: 10.1136/jitc-2023-006944. J Immunother Cancer. 2023. PMID: 37607769 Free PMC article. - Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza.
Werninghaus IC, Hinke DM, Fossum E, Bogen B, Braathen R. Werninghaus IC, et al. Mol Ther. 2023 Jul 5;31(7):2188-2205. doi: 10.1016/j.ymthe.2023.03.012. Epub 2023 Mar 16. Mol Ther. 2023. PMID: 36926694 Free PMC article. - Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin.
Grødeland G, Baranowska-Hustad M, Abadejos J, Blane TR, Teijaro J, Nemazee D, Bogen B. Grødeland G, et al. Front Immunol. 2020 Mar 25;11:431. doi: 10.3389/fimmu.2020.00431. eCollection 2020. Front Immunol. 2020. PMID: 32269566 Free PMC article. - A DNA Vaccine That Encodes an Antigen-Presenting Cell-Specific Heterodimeric Protein Protects against Cancer and Influenza.
Braathen R, Spång HCL, Hinke DM, Blazevski J, Bobic S, Fossum E, Bogen B. Braathen R, et al. Mol Ther Methods Clin Dev. 2020 Jan 25;17:378-392. doi: 10.1016/j.omtm.2020.01.007. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2020. PMID: 32128342 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials